Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 157Carcinoma, Transitional Cell 56Non-Muscle Invasive Bladder Neoplasms 30Urethral Neoplasms 24Carcinoma, Renal Cell 23Neoplasms 19Kidney Neoplasms 15Pancreatic Neoplasms 14Ovarian Neoplasms 14Neoplasm Metastasis 13Carcinoma, Non-Small-Cell Lung 13Prostatic Neoplasms 12Ureteral Neoplasms 11Urologic Neoplasms 9Colorectal Neoplasms 9Breast Neoplasms 9Lung Neoplasms 7Testicular Neoplasms 6Stomach Neoplasms 6Melanoma 6Sarcoma 5Urothelial Cancer 4Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Osteosarcoma 4Colonic Neoplasms 4Urogenital Neoplasms 3Triple Negative Breast Neoplasms 3Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Carboplatin 2zimberelimab 1sirtratumab vedotin 1sacituzumab govitecan 1olaparib 1avelumab 1Oxaliplatin 1Nivolumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Urothelial Cancer × Gemcitabine × Genitourinary × Clear all
NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting
827 enrolled 1 FDA
Genitourinary

Metastatic Urothelial Cancer

NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡